Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees is expected to continue raising capital to finance operations but has raised approximately $3.4 million net through ATM sales during Q1, improving cash position which ended at $3.3 million. With the potential new pipeline opportunity of Australian Chestnut extract and ongoing commercial initiatives for ARAKODA, the company may see increased product sales momentum and improved profitability in FY2026. However, risks to achieving these goals include balance sheet and liquidity risks, as well as clinical trial results and regulatory approvals for their product candidates.

Bears say

60 Degrees is a specialty pharmaceutical company with a focus on developing new therapies for infectious diseases. However, recent financials show a decline in product revenue and a growing cash deficit, indicating potential challenges in commercial and clinical developments. Additionally, risks such as failed clinical trials, dilutive capital raises, and lack of commercial success could impede the stock. Therefore, a Neutral rating is appropriate until there is more visibility on ARAKODA and tafenoquine's progress in the treatment of fungal, viral, and vector-borne diseases.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.